Hims & Hers Health (NYSE:HIMS) Trading Down 6.1% on Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS) traded down 6.1% during trading on Friday following insider selling activity. The stock traded as low as $26.58 and last traded at $26.74. 6,779,391 shares changed hands during trading, a decline of 33% from the average session volume of 10,044,754 shares. The stock had previously closed at $28.49.

Specifically, insider Michael Chi sold 17,303 shares of the business’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $27.97, for a total value of $483,964.91. Following the transaction, the insider now owns 193,601 shares of the company’s stock, valued at approximately $5,415,019.97. The trade was a 8.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $29.98, for a total transaction of $126,305.74. Following the completion of the transaction, the chief financial officer now owns 128,365 shares in the company, valued at approximately $3,848,382.70. This trade represents a 3.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Hims & Hers Health news, CFO Oluyemi Okupe sold 18,959 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $25.77, for a total transaction of $488,573.43. Following the completion of the transaction, the chief financial officer now owns 132,578 shares in the company, valued at approximately $3,416,535.06. This represents a 12.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on HIMS shares. Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. TD Cowen reaffirmed a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Finally, Morgan Stanley started coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $22.80.

Hims & Hers Health Stock Performance

The company has a market capitalization of $5.80 billion, a PE ratio of 60.37 and a beta of 1.25. The stock’s fifty day simple moving average is $26.37 and its 200-day simple moving average is $21.49.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter last year, the business earned ($0.04) earnings per share. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently added to or reduced their stakes in HIMS. Quest Partners LLC increased its stake in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the last quarter. CWM LLC boosted its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at $111,000. Quarry LP grew its stake in shares of Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after buying an additional 2,913 shares during the period. Finally, Amalgamated Bank increased its holdings in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after buying an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.